Table 2.
Open in new tab

Clinical characteristics of patients by the neutralizing antibody decay magnitude at 6-months post-second vaccination

Clinical parametersTotalDrop <50%Drop >50%P-value
n = 38n = 14n = 24
Gender, female, n (%)21 (55.3)8 (57.1)13 (54.2)0.859
Race, n (%)0.407
 Chinese30 (78.9)11 (78.6)19 (79.2)
 Malay1 (2.6)0 (0.0)1 (4.2)
 Indian2 (5.3)0 (0.0)2 (8.4)
 Others5 (13.2)3 (21.4)2 (8.3)
Age at first vaccination (years)a16.5 (14.4–19.1)17.1 (13.9–19.1)16.5 (14.5–19.2)0.904
Diagnosis, n (%)
 JIA19 (50.0)3 (21.4)16 (66.7)0.007
 SLE5 (13.2)4 (28.6)1 (4.2)0.052
Medications, n (%)
 Prednisolone5 (13.2)4 (28.6)1 (4.2)0.052
 MTX12 (31.6)2 (14.3)10 (41.7)0.147
 AZA1 (2.6)1 (7.1)0 (0.0)0.368
 MMF4 (10.5)3 (21.4)1 (4.2)0.132
 SSZ9 (23.7)2 (14.3)7 (29.2)0.438
 HCQ10 (26.3)8 (57.1)2 (8.3)0.002
 Anti-TNF15 (39.5)2 (14.3)13 (54.2)0.015
Clinical parametersTotalDrop <50%Drop >50%P-value
n = 38n = 14n = 24
Gender, female, n (%)21 (55.3)8 (57.1)13 (54.2)0.859
Race, n (%)0.407
 Chinese30 (78.9)11 (78.6)19 (79.2)
 Malay1 (2.6)0 (0.0)1 (4.2)
 Indian2 (5.3)0 (0.0)2 (8.4)
 Others5 (13.2)3 (21.4)2 (8.3)
Age at first vaccination (years)a16.5 (14.4–19.1)17.1 (13.9–19.1)16.5 (14.5–19.2)0.904
Diagnosis, n (%)
 JIA19 (50.0)3 (21.4)16 (66.7)0.007
 SLE5 (13.2)4 (28.6)1 (4.2)0.052
Medications, n (%)
 Prednisolone5 (13.2)4 (28.6)1 (4.2)0.052
 MTX12 (31.6)2 (14.3)10 (41.7)0.147
 AZA1 (2.6)1 (7.1)0 (0.0)0.368
 MMF4 (10.5)3 (21.4)1 (4.2)0.132
 SSZ9 (23.7)2 (14.3)7 (29.2)0.438
 HCQ10 (26.3)8 (57.1)2 (8.3)0.002
 Anti-TNF15 (39.5)2 (14.3)13 (54.2)0.015
a

Data are presented as median (interquartile range). A p-value <0.05 was considered statistically significant.

Table 2.
Open in new tab

Clinical characteristics of patients by the neutralizing antibody decay magnitude at 6-months post-second vaccination

Clinical parametersTotalDrop <50%Drop >50%P-value
n = 38n = 14n = 24
Gender, female, n (%)21 (55.3)8 (57.1)13 (54.2)0.859
Race, n (%)0.407
 Chinese30 (78.9)11 (78.6)19 (79.2)
 Malay1 (2.6)0 (0.0)1 (4.2)
 Indian2 (5.3)0 (0.0)2 (8.4)
 Others5 (13.2)3 (21.4)2 (8.3)
Age at first vaccination (years)a16.5 (14.4–19.1)17.1 (13.9–19.1)16.5 (14.5–19.2)0.904
Diagnosis, n (%)
 JIA19 (50.0)3 (21.4)16 (66.7)0.007
 SLE5 (13.2)4 (28.6)1 (4.2)0.052
Medications, n (%)
 Prednisolone5 (13.2)4 (28.6)1 (4.2)0.052
 MTX12 (31.6)2 (14.3)10 (41.7)0.147
 AZA1 (2.6)1 (7.1)0 (0.0)0.368
 MMF4 (10.5)3 (21.4)1 (4.2)0.132
 SSZ9 (23.7)2 (14.3)7 (29.2)0.438
 HCQ10 (26.3)8 (57.1)2 (8.3)0.002
 Anti-TNF15 (39.5)2 (14.3)13 (54.2)0.015
Clinical parametersTotalDrop <50%Drop >50%P-value
n = 38n = 14n = 24
Gender, female, n (%)21 (55.3)8 (57.1)13 (54.2)0.859
Race, n (%)0.407
 Chinese30 (78.9)11 (78.6)19 (79.2)
 Malay1 (2.6)0 (0.0)1 (4.2)
 Indian2 (5.3)0 (0.0)2 (8.4)
 Others5 (13.2)3 (21.4)2 (8.3)
Age at first vaccination (years)a16.5 (14.4–19.1)17.1 (13.9–19.1)16.5 (14.5–19.2)0.904
Diagnosis, n (%)
 JIA19 (50.0)3 (21.4)16 (66.7)0.007
 SLE5 (13.2)4 (28.6)1 (4.2)0.052
Medications, n (%)
 Prednisolone5 (13.2)4 (28.6)1 (4.2)0.052
 MTX12 (31.6)2 (14.3)10 (41.7)0.147
 AZA1 (2.6)1 (7.1)0 (0.0)0.368
 MMF4 (10.5)3 (21.4)1 (4.2)0.132
 SSZ9 (23.7)2 (14.3)7 (29.2)0.438
 HCQ10 (26.3)8 (57.1)2 (8.3)0.002
 Anti-TNF15 (39.5)2 (14.3)13 (54.2)0.015
a

Data are presented as median (interquartile range). A p-value <0.05 was considered statistically significant.

Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close